# Magnesium Taurine Cognition Randomized Trial: What the Evidence Says
Canonical: https://www.migaku.app/guides/magnesium-taurine-cognition-randomized-trial-evidence-review
Category: evidence-review
Summary: Magnesium Taurine Cognition Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pas
Last reviewed: 2026-08-04
Reviewed by: Migaku Evidence Review
# Magnesium Taurine Cognition Randomized Trial: What the Evidence Says

## Quick Answer

Magnesium Taurine Cognition Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 systematic review, 1 preclinical study.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Risk reduction and precision prevention across the Alzheimer’s disease continuum: a systematic review of clinical trials combining multidomain lifestyle interventions and pharmacological or nutraceutical approaches | systematic review | 1 | 2025-12-01 | 10.1016/j.tjpad.2025.100367 |
| The Integrative Personalized Functional Medicine Approach to Reverse Cognitive Decline: Academic Experience of the First 51 Patients Case Series | preclinical study | 4 | 2026-05-27 | 10.1177/27536130261452680 |

## What The Sources Report

- Additionally, the failure of numerous pharmacological and non-pharmacological single-domain interventions in AD underscores the limitations of targeting single-disease mechanisms or single risk factors. [Bereczki Erika (2025); evidence level 1]
- There is a clear need for strategies addressing multiple risk factors and biological pathways simultaneously, with early intervention in the ADRD continuum being crucial for an optimal preventive effect. [Bereczki Erika (2025); evidence level 1]
- This case series presents outcomes of the first 51 patients who participated in one such program and aims to add to preliminary evidence regarding the efficacy of a personalized multimodal integrative functional medicine approach to cognitive decline in the context of prior uncontrolled and ongoing controlled trials. [Kogan Mikhail (2026); evidence level 4]
- Management of vascular risk factors (hypertension, hyperlipidemia, diabetes), tobacco and alcohol counseling, and hearing evaluation were conducted through participants' primary clinicians, consistent with standard dementia prevention guidelines. [Kogan Mikhail (2026); evidence level 4]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For magnesium taurine cognition randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Bereczki Erika (2025). Risk reduction and precision prevention across the Alzheimer’s disease continuum: a systematic review of clinical trials combining multidomain lifestyle interventions and pharmacological or nutraceutical approaches. DOI: 10.1016/j.tjpad.2025.100367. PMCID: PMC12627892. PMID: 41145344. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12627892/
- Kogan Mikhail (2026). The Integrative Personalized Functional Medicine Approach to Reverse Cognitive Decline: Academic Experience of the First 51 Patients Case Series. DOI: 10.1177/27536130261452680. PMCID: PMC13219804. PMID: 42221535. License: https://creativecommons.org/licenses/by-nc/4.0/ https://creativecommons.org/licenses/by-nc/4.0/ https://us.sagepub.co.... https://pmc.ncbi.nlm.nih.gov/articles/PMC13219804/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.